Chee, A. | Search bioRxiv

bioRxiv2026

Changing the Fate of Dystrophin-Deficient Myoblasts via Hetero ligand Nanoclusters on Biomaterial Surface: Effects of Integrin-Syndecan or Dystroglycan Crosstalk

Engineering skeletal muscle tissue regeneration, particularly in dystrophin-deficient muscles is dependent on facilitating myogenesis and recovery of myotube structure and function, which can be challenging due to compromised cell-extracellular matrix (ECM) interactions. The current study explored the potential impact of enhancing dystrophin-associated protein complex and focal adhesion formation and the interaction with associated target receptors to improve cellular response in both normal and Duchenne muscular dystrophy (Dmd) mutant myoblasts. This was achieved by multivalent dual ligands functionalization of RAFT-synthesized copolymer with fibronectin- and laminin-derived adhesion peptides (RGD, AG73, and A2G80) and their clustering at the biointerface. Our findings demonstrated the synergistic effect of integrin-syndecan/dystroglycan engagement and their clustering on enhancing myoblast adhesion, proliferation, and differentiation, partially overcoming the deficits caused by loss of dystrophin. Furthermore, enhanced focal adhesion formation and elevated receptor localization, particularly dystroglycan, at the sarcolemma were associated with improved structural organization, mechanical stability, and neuromuscular connectivity of myotubes. These results suggest a novel insight into harnessing next-generation molecularly engineered biomaterials with robust interaction with cells mechanosensors for advancing skeletal muscle tissue engineering, offering potential applications in the regeneration of dystrophic muscle and the development of neuromuscular disease models for drug testing. O_FIG O_LINKSMALLFIG WIDTH=174 HEIGHT=200 SRC="FIGDIR/small/717576v1_ufig1.gif" ALT="Figure 1"> View larger version (55K): org.highwire.dtl.DTLVardef@16c6b87org.highwire.dtl.DTLVardef@107a84borg.highwire.dtl.DTLVardef@1b9e4ddorg.highwire.dtl.DTLVardef@160a9a7_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical Abstract/ToCC_FLOATNO Current work developed molecularly engineered biomaterial surfaces with nanoscale clustering of integrin-, syndecan-, and/or dystroglycan-binding peptides for skeletal muscle tissue regeneration. By controlling peptide distribution and type at the biointerface, cell adhesion, proliferation, and differentiation were modulated in dystrophin-deficient myoblasts. Accordingly, the results demonstrated significant improvement in myotube structural organization, mechanical stiffness, and their innervation in response to heteronanoclusters. C_FIG

bioengineering↗

bioRxiv2026

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis

Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin (mutCALR). This yields a common neoepitope that binds to, and activates, the thrombopoietin receptor and results in display of the oncoprotein on the extracellular membrane of disease-driving cells, exposing a therapeutic vulnerability. Here, we present a first-in-class chimeric antigen receptor (CAR) T-cell therapy that specifically targets mutCALR+ cells, both in vitro and in vivo. The CAR T-cell therapy selectively depleted mutCALR+ stem cells from patients with myelofibrosis while sparing healthy stem cells, and improved survival in mutCALR leukemia xenografts. To mimic myelofibrotic marrow, we developed a bespoke human chimeroid model and showed no decrease in the potency of CAR T cell-mediated target cell killing even in a fibrotic tumor microenvironment. We also devised a method to boost cell surface expression of mutCALR in CD34+ cells isolated from patients with accelerated/blast phase MPN (defined as >10 % blasts in peripheral blood or bone marrow), enhancing CAR T targeting. This study presents a therapeutic with potential to eradicate mutCALR-driven malignancies and highlights an innovative strategy to evaluate blood cancer-targeting immunotherapies in a relevant TME. One Sentence SummaryA first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.

cancer biology↗